Most Promising Applications of Artificial Intelligence (AI) in Healthcare Segment

Genetic Disorders

A Turning Point: INGREZZA’s Impact on Huntingto...

Huntington’s disease is an incurable, rare genetic, progressive neurodegenerative disorder. According to the National Organization for Rare Disorders (NORD), about 30,000 people in the United State...

Sep 18, 2023

Pharma News for Faron, Roche, Ergomed, Menarini
Daiichi Sankyo’s Trastuzumab Deruxtecan; ODD to Bexmarilimab for AML; Roche’ Alecensa; Ergomed Aims To Go Private; Tagraxofusp Receives ODD in Japan for BPCDN; FDA Fast Track Designation to Abliva’s KL1333

FDA Grants Breakthrough Therapy Designations to Trastuzumab Deruxtecan for HER2+ Solid Tumors, Including mCRC ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted two additional Breakthrough Therapy Designations (BTDs) in the United States for the treatment of adult patients with unresectable or metastati...

Find More
fabry-disease-treatment
Fabry Disease – A Market Perspective On The Emerging Pipeline

Fabry disease is a rare hereditary lysosomal storage disorder that is caused by mutation in the GLA gene located on the X chromosome. The defect leads to the deficiency of an enzyme called alpha-galactosidase A, responsible for the breakdown of globotriaosylceramide (Gb3). The accumulation of the fatty substance le...

Find More
homozygous-familial-hypercholesterolemia-treatment
Labyrinth of LDL-C: Navigating Challenges in Homozygous Familial Hypercholesterolemia Treatment

Homozygous familial hypercholesterolemia (HoFH) is a rare form of familial hypercholesterolemia, an autosomal-dominant genetic disorder of lipid metabolism characterized by strikingly elevated levels of low-density lipoprotein cholesterol (LDL-C).  Heterozygous Familial Hypercholesterolemia vs. Homozygous F...

Find More

More Views & Analysis

Pharma News for Gilead, Incannex, Avidity
Eylea HD Injection 8 Mg Approved By FDA; Veopoz Receives FDA Approval for CHAPLE Disease Treatment; FDA Places Second Partial Clinical Hold on AML Enrollment for Magrolimab Trials; FDA Approval to Incannex’s Sleep Apnoea Clinical Trial; FDA Orphan Drug Designation to Avidity’s AOC 1044; Orphan Drug Designation to CanariaBio’s MAb-AR20.5

Eylea HD Injection 8 Mg Approved By FDA for Treatment of Wet AMD, DME, and Diabetic Retinopathy The FDA has approved Regeneron Pharmaceuticals’ EYLEA HD (aflibercept) Injection of 8 mg for the treatment of patients with wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retin...

Find More

Pharma News for Janssen, Galera, Genprex
J&J’s 2-in-1 Tablet for Prostate Cancer; FDA Approves TALVEY for Heavily Pretreated Multiple Myeloma; PDS Biotech Updated on VERSATILE-003 Trial; FDA Issues CRL to NDA for Avasopasem in Radiotherapy-Induced Severe Oral Mucositis in HNC; FDA Orphan Drug Designation to Genprex’s REQORSA; FDA Orphan Drug Designation to Bloomsbury’s BGT-OTCD

FDA Clears J&J’s 2-in-1 Tablet for Prostate Cancer Johnson & Johnson's Janssen Pharmaceutical Companies stated that the US Food and Drug Administration (FDA) had approved AKEEGA (niraparib and abiraterone acetate), the first-and-only dual-action tablet combining a PARP inhibitor including abiraterone ace...

Find More

Diagnostic Precision: The Rise of Medical Imaging Technologies and Market Trends

In recent years, significant strides have been made in the realm of medical imaging, ushering in a new era of possibilities for healthcare professionals engaged in diagnosing, treating, and monitoring a diverse array of medical conditions and diseases. The convergence and developments in the state-of-the-art techno...

Find More

Pharma News for GSK, Biogen, Citius
FDA Expands GSK’s Jemperli Approval; Biogen to Acquire Reata Pharma; Enhertu Shows Survival Boost in HER2+ Solid Tumors; FDA Rejects Citius’ Revived IL-2 Therapy; FDA Fast Track designation to IVS-3001 for RCC; EU Orphan Drug Designation to Biohaven’s Taldefgrobep Alfa

FDA Expands GSK’s Jemperli Approval for Endometrial Cancer GSK plc announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab) in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for the treatment of adult patients with mismatch repair deficient...

Find More

Pharma News for Gilead, Ambrx, Mirati
Gilead’s Magrolimab Plus Azacitidine for MDS; FDA Approveds VANFLYTA for Newly Diagnosed AML; FDA Awards Fast Track Designation to ARX517 mCRPC; EMA Rejects Mirati’s Krazati; Harmony Phase III Pitolisant Trial for PWS Patients; Belite Bio’s Phase 3 DRAGON Trial of Tinlarebant for STGD

Gilead To Discontinue Phase III ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS Gilead Sciences, Inc. reported that the Phase III ENHANCE study in higher-risk myelodysplastic syndromes (MDS) has been halted due to futility based on a planned analysis. The safety data in this trial are consistent ...

Find More

biomarins-roctavian-first-hemophilia-a-gene-therapy
The Future is Here: BioMarin’s Roctavian First Hemophilia A Gene Therapy Paving the Way for a Cure

Hemophilia A is a rare genetic bleeding disorder that primarily affects males. Hemophilia A is the most common type of hemophilia, accounting for approximately 80% of all cases. It is estimated to occur in about 1 in 5,000 to 10,000 male births. As per the Centers for Disease Control (CDC) (2020), the estimated pre...

Find More

Primary Progressive Aphasia (PPA) is a rare neurological disorder that results from the damages to t.....

Find More

Virtual clinical trials (VCTs) are site-less clinical trials, which utilizes technology along with t.....

Find More

A complex genetic condition, Prader-Willi syndrome (PWS) is a result of the loss of the functioning .....

Find More

HIV-associated lipodystrophy (HAL), is a condition characterized by the redistribution of adipose ti.....

Find More

A genetic disorder, Duchenne Muscular Dystrophy (DMD), is a progressive form of muscular dystrophy w.....

Find More

Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare acquired disease that leads to the destruction o.....

Find More